Netta Blondheim-Shraga, PhD Appointed as VP R&DAntalPearl-Lendner, Adv. Appointed as Chief Legal Counsel
NEW YORK, May 12, 2022 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced two senior management appointments. Netta Blondheim Shraga, PhD has been appointed as VP, Research & Development, and AntalPearl-Lendner, Adv. has been appointed to the newly created position of Chief Legal Counsel. Both will report directly to Chaim Lebovits, CEO.
"We are thrilled to welcome Netta and Antal, each of whom brings valuable experience in their respective areas of R&D and Legal Affairs," said Chaim Lebovits, Chief Executive Officer of BrainStorm. "As we prepare the company for growth, it is important that we continue to build out our senior executive team and attract professionals with the appropriate skillsets. We look forward to leveraging their backgrounds as we execute on our mission to bring autologous cell therapies to patients with debilitating neurodegenerative diseases."
Dr. Blondheim-Shraga will be responsible for advancing the company's pipeline and steering the R&D team towards significant breakthroughs in the field of cell therapy and development of novel solutions to positively impact patients' health. Dr. Blondheim-Shraga joins BrainStorm with over 14 years of translational research experience in academic, biotech and pharma settings, having led teams in Israel, USA and China, combining scientific, entrepreneurial and management skills. Prior to joining BrainStorm, she was Project Leader on the Academic Affairs team at Teva Pharmaceuticals, Israel. In this role, she managed a portfolio of diverse and highly impactful strategic scientific collaborations with Teva's academic partners and managed Teva's involvement in several international consortia. Prior to Teva, she was Study Director and Senior Scientist at CrownBio, San Diego, CA. Earlier in her career, she was a Senior Scientist at Lifemap Sciences LTD in Tel-Aviv and served as Scientific Advisor to ImmunoHiTech LTD, Ramat Hasharon, Israel for several years. Dr. Blondheim-Shraga received a PhD from the Faculty of Medicine, Bar-Ilan University, Safed, Israel, an MSc Med from The Faculty of Medicine, Tel Aviv University, Israel and a BSc Med from The Faculty of Medicine, Hebrew University Jerusalem, Israel.
AntalPearl-Lendner, Adv. is an experienced bilingual attorney with a proven track record in legal and business development capacities. Prior to joining Brainstorm, Ms. Pearl-Lendner spent 8 years at Mizrahi-Tefahot Bankin Israel where her responsibilities included spearheading bank-wide complex projects, negotiating large scale international contracts and providing ongoing advice regarding the international activities of the bank. Before her tenure at the bank, she worked at GE Capital in Chicago and Connecticut, USA, where she served in GE's premier commercial leadership program, working in business development, strategy & analytics. Earlier in her career, Ms. Pearl-Lendner was an Associate Attorney in the international department of Caspi & Co. Advocates & Notaries in Tel Aviv, Israel. In this role she represented clients in M&A transactions and led due diligence processes for investments ranging from $5M to $350M. Ms. Pearl-Lendner received an MBA from the MIT Sloan School of Management in Cambridge, Massachusetts and an LLB from Tel Aviv University.
AboutBrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).
Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect,""likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our products and services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; the impacts of the COVID-19 pandemic on our clinical trials, supply chain, and operations; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investor Relations:John MullalyLifeSci Advisors, LLCPhone: +1 617-429-3548 [emailprotected]
Media:Uri Yablonka[emailprotected]
SOURCE BrainStorm Cell Therapeutics Inc.
See the article here:
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal USA - English - USA - English - PR Newswire
- Home | Department of Animal Science - September 25th, 2022
- Blood, sweat, and many miles for cellular therapy - Martha's Vineyard Times - July 27th, 2022
- An Experimental Treatment Failed in Mice, and Researchers Did the Right Thing: They Published About It - UConn Today - UConn - June 22nd, 2022
- Is Stem Cell Research Illegal in The United States? - April 6th, 2022
- The Pfizer-BioNTech vaccine explained: Whats in it and how does it work - KELOLAND.com - October 16th, 2021
- COVID SCIENCE-Coronavirus may have reached U.S. last December; some cancer therapies may prolong infectiousness - Reuters - December 3rd, 2020
- Yale New Haven Health Docs: Interpreting the Uptick in Covid-19 Cases - Greenwich Free Press - October 31st, 2020
- Stem Cell Therapy Connecticut - Boston Stem Cell Center - October 24th, 2020
- Buzzing to Rebuild Broken Bone: Its Electric! - UConn Today - July 2nd, 2020
- Connecticut governor seeks 3rd party review of nursing homes - Thehour.com - June 13th, 2020
- The Growing Prison Pandemic Wasn't Inevitable, and It's Not Too Late to Fight It - brennancenter.org - April 9th, 2020
- Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular... - April 6th, 2020
- Stem cells that can grow new bone discovered by researchers - Drug Target Review - March 7th, 2020
- University of Connecticut Reverses Prader-Willi Syndrome in Lab by Restoring Silent Genes - Gilmore Health News - January 5th, 2020
- Comparing of Brainstorm Cell Therapeutics Inc. (BCLI) and Cara Therapeutics Inc. (NASDAQ:CARA) - The Broch Herald - December 15th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 19th, 2019
- Center for Regenerative Medicine and Skeletal Development ... - September 14th, 2019
- Connecticut Stem Cells | Stem Cell TV - September 10th, 2019
- Our Doctors - MD Stem Cells - April 6th, 2019
- Hartford, CT - Stem Cells Transplant Institute - January 24th, 2019
- Connecticut Pours Millions Into Embryonic Stem Cell ... - December 21st, 2018
- Stem Cell Transplants - Connecticut Children's Medical Center - November 14th, 2018
- Stem Cell Research Program - Grants - portal.ct.gov - September 24th, 2018
- Stem Cell Research Program - portal.ct.gov - June 23rd, 2018
- Regenerative Therapies | DAVID KLOTH, MD | Connecticut ... - June 23rd, 2018
- FDA Response - U.S. Stem Cell Clinic - October 14th, 2017
- Connecticut & New England Stem Cell Injection Therapy ... - September 24th, 2017
- EBAL schools to raise funds for San Ramon Valley alum Jake Javier - SFGate - August 6th, 2017
- Jeff Jacobs: Hall Of Fame Coach Holowaty Fights Illness And Gives Back - Hartford Courant - July 7th, 2017
- Biological Industries USA Signs Agreement with Mill Creek Life ... - Business Wire (press release) - March 12th, 2017
- Stormy Chamberlain - Faculty Directory UConn Health - November 27th, 2016
- Faculty Directory UConn Health - November 25th, 2016
- Cells Harvested From Human Urine Used to Make Stem Cells - September 18th, 2016
- Skeletal muscle stem cells - National Center for ... - August 22nd, 2016
- StemCONN - July 31st, 2016
- STEM CELL TECHNOLOGIST with Yale-New Haven Hospital | 31281935 - October 5th, 2015
- Stem cell research blooms at Yale and in Connecticut - October 5th, 2015
- Stem Cells jobs - Science Careers - October 1st, 2015
- Bridgeport Connecticut Stem Cell Research | Bridgeport CT ... - June 20th, 2015
- Stem Cells: Thematic Research Areas - June 4th, 2015
- 365 days: Nature's 10 - December 18th, 2014
- Stem cells - Dr Olivier Clinic - November 16th, 2014
- D.C.s best places to get beautiful: Nusta Spa and Bang Salon - October 16th, 2014
- Connecticut Stem Cell Therapy | Stem Cell Treatments - September 25th, 2014
- Walk To End Alzheimers - September 16th, 2014
- YaleNews | How to tell good stem cells from the bad: Yale ... - September 6th, 2014
- Connecticut (Stem Cell) - what-when-how - September 5th, 2014
- How to tell good stem cells from the bad: Yale researchers answer key question - September 5th, 2014
- Stem Cell Treatment for Spinal Cord Injury (SCI) with CT ... - August 23rd, 2014
- UConn-Wesleyan University Stem Cell Core UConn Health - August 23rd, 2014
- Connecticut Catholics respond to ALS ice bucket controversy - August 23rd, 2014
- Induced Pluripotent Stem Cell Services Induced ... - August 23rd, 2014
- Stem Cell Institute: Cell and Genome Sciences: UConn Health - August 22nd, 2014